Greenwich LifeSciences, Inc. (GLSI) Bundle
A Brief History of Greenwich LifeSciences, Inc. (GLSI)
Company Formation
Company Formation
Greenwich LifeSciences, Inc. was founded in 2008 and is headquartered in Stafford, Texas. The company focuses on developing immunotherapy treatments, particularly for breast cancer.
Clinical Development
The company’s lead product candidate, GP2, is a peptide vaccine designed to prevent recurrence in patients with HER2-positive breast cancer. The Phase II clinical trial, known as the "GP2 trial," was initiated in 2016, with a primary endpoint of disease-free survival.
Financial Milestones
As of December 31, 2022, Greenwich LifeSciences reported total assets of approximately $23.6 million, with cash and cash equivalents constituting about $12.5 million.
In 2021, the company completed a public offering that raised $12 million to fund its clinical trials.
Market Performance
Greenwich LifeSciences, Inc. went public through an initial public offering (IPO) on the NASDAQ in 2020, trading under the ticker symbol GLSI. The initial share price was set at $5.00.
As of October 2023, the stock price fluctuated around $20.00 per share, reflecting a market capitalization of approximately $140 million.
Regulatory Approvals
In April 2023, Greenwich LifeSciences received Breakthrough Therapy Designation from the FDA for GP2, expediting the development process due to the unmet medical need for adjuvant treatments in breast cancer.
Partnerships and Collaborations
The company has established strategic alliances with multiple research institutions to advance its clinical research. Notably, a collaboration with the University of Texas MD Anderson Cancer Center facilitated significant advancements in immunotherapy research.
Research and Development Expenditure
In 2022, Greenwich LifeSciences reported R&D expenses totaling $8 million, which represents a commitment to advancing its clinical pipeline.
| Year | Revenue ($ million) | R&D Expenses ($ million) | Total Assets ($ million) | Cash and Cash Equivalents ($ million) |
|---|---|---|---|---|
| 2020 | $0.5 | $3.0 | $10.0 | $5.0 |
| 2021 | $1.0 | $4.0 | $15.0 | $7.0 |
| 2022 | $2.5 | $8.0 | $23.6 | $12.5 |
Future Outlook
Looking ahead, Greenwich LifeSciences aims to commence Phase III clinical trials for GP2, targeting an estimated market opportunity of $7 billion for HER2-positive breast cancer therapies.
The company also plans to expand its research into other cancers, further increasing its product pipeline and potential market reach.
A Who Owns Greenwich LifeSciences, Inc. (GLSI)
Corporate Overview
Greenwich LifeSciences, Inc. (GLSI) is a biotechnology company focused on the development and commercialization of immunotherapies for cancer treatment. As of October 2023, the company trades on the NASDAQ under the ticker symbol GLSI.
Ownership Structure
As of the most recent filings, the ownership structure of GLSI is characterized by a combination of institutional investors, individual shareholders, and company insiders.
| Ownership Type | Percentage of Shares Owned | Number of Shares |
|---|---|---|
| Institutional Investors | 45% | 1,800,000 |
| Insider Ownership | 20% | 800,000 |
| Retail Investors | 35% | 1,400,000 |
Major Institutional Shareholders
Some of the larger institutional stakeholders include the following:
| Institution Name | Shares Held | Percentage of Ownership |
|---|---|---|
| BlackRock, Inc. | 600,000 | 15% |
| Vanguard Group | 500,000 | 12.5% |
| State Street Corporation | 300,000 | 7.5% |
Insider Ownership Details
The company’s insiders include executives and board members who play crucial roles in its operations.
| Name | Title | Shares Owned |
|---|---|---|
| Sudhir Agrawal | CEO | 300,000 |
| Patricia Flanagan | Chairperson | 250,000 |
| James L. Wilkins | CFO | 150,000 |
Shareholder Meetings and Voting
Greenwich LifeSciences holds annual shareholder meetings where ownership can influence company decisions, with voting rights correlated to share ownership.
Recent Stock Performance
The stock performance of GLSI reflects its market activities:
| Metric | Value |
|---|---|
| Current Stock Price | $14.75 |
| Market Capitalization | $590 million |
| 52-Week High | $19.50 |
| 52-Week Low | $8.20 |
Market Sentiment and Analysis
The market sentiment surrounding GLSI is influenced by various factors, including ongoing clinical trials and corporate announcements. Analysts project a potential growth trajectory based on pipeline developments.
Greenwich LifeSciences, Inc. (GLSI) Mission Statement
Company Overview
Greenwich LifeSciences, Inc. (GLSI) focuses on the development of innovative therapies for treating cancer. The company aims to leverage its proprietary technology to enhance patient outcomes and improve quality of life.
Mission Statement
The mission of Greenwich LifeSciences is to advance the therapeutic potential of its lead product candidate, GP2, to provide effective solutions for breast cancer patients, specifically those who are HER2-positive.
Core Values
- Innovation: Continuous improvement and advancement in cancer therapies.
- Patient-Centric: Focused on patient needs and outcomes.
- Integrity: Commitment to ethical practices in research and development.
- Collaboration: Engaging with healthcare professionals to enhance treatment efficacy.
Financial Performance
As of the third quarter of 2023, Greenwich LifeSciences reported the following financial metrics:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $2.5 million |
| Net Loss | $(3.1 million) |
| Total Assets | $15.4 million |
| Total Liabilities | $2.3 million |
| Cash and Cash Equivalents | $10.2 million |
Product Development
Greenwich LifeSciences is engaged in the clinical development of GP2, an immunotherapy designed to prevent recurrences of breast cancer. Notable milestones include:
- Phase II Study: Completed with promising results.
- FDA Interaction: Ongoing discussions regarding future regulatory pathways.
- Patent Portfolio: Multiple patents granted for GP2 and its applications.
Market Position
The company operates within the biotechnology sector, particularly focusing on oncological solutions. As of 2023, the U.S. breast cancer market is estimated at $24 billion, with an expected growth rate of 5% annually.
Strategic Goals
- Expand Clinical Trials: Increase the scale of trials for GP2.
- Enhance Partnerships: Seek collaborations with leading research institutions.
- Elevate Awareness: Initiatives to inform and educate healthcare providers on GP2.
How Greenwich LifeSciences, Inc. (GLSI) Works
Overview of Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of immune-based therapies for the treatment of cancer. The company’s primary asset is its lead product candidate, GP2, which targets breast cancer.
Corporate Structure and Leadership
- CEO: Dr. Stacie M. Jones
- Chairman: Dr. Richard H. H. T. Liu
- Board Members: 6 members with expertise in oncology and immunotherapy
Financial Performance
As of Q3 2023, GLSI reported the following financial numbers:
| Financial Metric | Q3 2023 Amount | 2022 Amount |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income (Loss) | ($3.1 million) | ($2.5 million) |
| Total Assets | $16.5 million | $12.0 million |
| Total Liabilities | $1.0 million | $0.8 million |
| Cash and Cash Equivalents | $15.5 million | $10.5 million |
Clinical Development Pipeline
GP2 is in Phase III clinical trials, and the following statistics are associated with its development:
- Indication: HER2-positive breast cancer
- Phase III Trial Size: 300 patients
- Primary Endpoint: Disease-free survival
- Projected Completion: Q4 2024
Market Position and Competitive Landscape
GLSI operates in a competitive market with several other companies focusing on cancer immunotherapy, including:
-
Competitors:
- Roche
- Merck & Co.
- Amgen
- Market Size for HER2-positive Breast Cancer Treatments: Expected to reach $12 billion by 2025
Investments and Funding
Greenwich LifeSciences has raised funds through various means:
- Public Offerings (since inception): $20 million
- Grants and Collaborations: $5 million from governmental and private organizations
- Stock Performance: The stock price as of October 2023 is $6.75, with a market capitalization of approximately $134 million.
Strategic Partnerships and Collaborations
The company has established partnerships to enhance its research and development capabilities:
-
Collaborators:
- Research institutions
- Clinical trial organizations
- Notable Partnership: Partnership with the University of Texas for GP2 development
Future Outlook
Looking ahead, GLSI aims to:
- Final Phase III Trial Results: Expected by late 2024
- Regulatory Approvals: Targeting FDA submission in early 2025
- Expansion: Growth into other oncology indications with GP2
How Greenwich LifeSciences, Inc. (GLSI) Makes Money
Revenue Sources
Greenwich LifeSciences, Inc. (GLSI) primarily generates revenue through its focus on developing and commercializing innovative therapeutics for cancer patients. As of the latest report, the company's focus is on the development of GP2, a peptide-based therapy designed to prevent breast cancer recurrence.
Product Development Pipeline
GLSI's revenue potential is highly tied to its product pipeline. The significant components include:
- GP2: A peptide vaccine therapy targeting breast cancer.
- Success from clinical trials that lead to commercialization opportunities.
- Potential collaborations or licensing agreements with larger pharmaceutical companies.
Financial Performance
As of Q2 2023, GLSI reported:
| Financial Metrics | Q2 2023 | Q1 2023 | Year End 2022 |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Net Loss | ($1.3 million) | ($1.2 million) | ($5 million) |
| Cash and Cash Equivalents | $11.5 million | $13 million | $14 million |
| Total Assets | $12 million | $13.2 million | $15 million |
| Market Capitalization | $67 million | $60 million | $55 million |
Funding and Investment
Greenwich LifeSciences has historically relied on financing to fund its operations. Key funding events include:
- Public offerings: GLSI raised approximately $11 million in its 2021 public offering.
- Institutional investments: Considerable investments from institutional investors, particularly during capital raises in 2022.
- Grant funding: Availability of non-dilutive grant funding for specific cancer research initiatives.
Collaborations and Partnerships
The company seeks partnerships to expand its reach and enhance its revenue potential:
- Strategic alliances with biotech firms can lead to co-development agreements.
- Licensing agreements allowing for commercialization support.
- Partnerships with academic institutions for research and development initiatives.
Market Trends and Opportunities
GLSI operates in a rapidly evolving healthcare landscape:
- The global cancer therapeutics market is projected to reach approximately $200 billion by 2026.
- Increasing demand for personalized medicine and targeted therapies.
- Opportunities arising from unmet medical needs in breast cancer treatments.
Conclusion of Financial Outlook
While Greenwich LifeSciences currently reports no revenue, the market dynamics and potential partnerships create a landscape with promising revenue opportunities in the near future, particularly tied to successful trial outcomes and product launches.
Greenwich LifeSciences, Inc. (GLSI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support